When factoring in what is now known
about breast cancer biology and heterogeneity, breast conserving therapy (BCT) may offer a greater survival benefit over mastectomy to women with early stage, hormone - receptor positive disease, according to research from The University of Texas MD Anderson Cancer Center.
«Forty years ago, very little was known
about breast cancer disease
biology — such as subtypes, differences in radio - sensitivities, radio - resistances, local recurrence and in metastatic potential,» explains Bedrosian, the study's senior author.